Loading…
SAB Biotherapeutics, Inc. is projected to rise to $4.53 by 2027, a +27% move from its current price of $3.57. SABS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $3.49 | $3.57 | $3.66 | -0.01% |
| Aug 4 | $3.45 | $3.57 | $3.69 | -0.02% |
| Aug 5 | $3.42 | $3.57 | $3.72 | -0.03% |
| Aug 6 | $3.40 | $3.57 | $3.74 | -0.04% |
| Aug 7 | $3.38 | $3.57 | $3.76 | -0.06% |
| Aug 8 | $3.37 | $3.57 | $3.78 | -0.07% |
| Aug 9 | $3.35 | $3.57 | $3.80 | -0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.35 | $3.57 | $3.80 | -0.08% |
| Week 2 | $3.26 | $3.56 | $3.90 | -0.16% |
| Week 3 | $3.19 | $3.56 | $3.97 | -0.24% |
| Week 4 | $3.14 | $3.56 | $4.04 | -0.31% |
| Week 5 | $3.09 | $3.56 | $4.09 | -0.39% |
| Week 6 | $3.05 | $3.55 | $4.14 | -0.47% |
| Week 7 | $3.01 | $3.55 | $4.19 | -0.55% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate, SAB-142, is in Phase 2b clinical trials for the treatment of autoimmune type 1 diabetes.
The company was founded in 2014 and is headquartered in Miami Beach, Florida.
SAB Biotherapeutics, Inc. trades under the symbol SABS. The current price is $3.62 and the company holds a market capitalization of $276.8M. It is ranked 3581 by market capitalization among listed assets.
A major floor 12.9% below — a decisive break under it would weaken the trend.
The nearest floor, 3.6% below — buyers have tended to step in here.
The nearest ceiling, 12.0% above — a clean break opens room to run.
A major ceiling 18.5% above — clearing it would confirm fresh momentum.
Key SABS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SABS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.50 | Buy | $3.53 | Buy |
| MA 10 | $3.53 | Buy | $3.55 | Buy |
| MA 20 | $3.64 | Sell | $3.61 | Sell |
| MA 50 | $3.66 | Sell | $3.67 | Sell |
| MA 100 | $3.75 | Sell | $3.69 | Sell |
| MA 200 | $3.73 | Sell | $3.55 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.69 | Neutral |
| Stoch RSI (14) | 99.00 | Sell |
| CCI (20) | -37.95 | Neutral |
| Williams %R (14) | -42.22 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -1.38 | Sell |
| Bollinger %B (20,2) | 0.38 | Neutral |
| Stochastic %K (14) | 57.78 | Neutral |
| TRIX (15) | -0.19 | Sell |
| Awesome (5,34) | -0.22 | Sell |
| Ultimate (7,14,28) | 44.63 | Neutral |
| Momentum (10) | 0.03 | Buy |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 3.51 | Buy |
| ADX (14) | 12.36 | Neutral |
| ATR (14) | 0.07 | Info |
The 30-day technical picture shows a NEUTRAL sentiment with RSI(14) at 40. The 50-day simple moving average sits at $3.72 and the 200-day simple moving average at $3.64, providing a narrow near-term trend setup. Support is noted at $3.31 and resistance at $4.00, framing a shallow trading range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.31 | $3.57 | $4.59 | 0% | Neutral | |
| $3.66 | $4.53 | $5.91 | +27% | Bullish | |
| $4.57 | $5.80 | $7.82 | +62% | Bullish | |
| $4.69 | $6.08 | $8.41 | +70% | Bullish | |
| $4.99 | $6.58 | $9.30 | +84% | Bullish | |
| $5.45 | $7.30 | $10.52 | +105% | Bullish | |
| $5.52 | $7.50 | $11.00 | +110% | Bullish | |
| $5.96 | $8.22 | $12.24 | +130% | Bullish | |
| $6.86 | $9.57 | $14.47 | +168% | Bullish | |
| $8.00 | $11.30 | $17.31 | +217% | Bullish | |
| $9.92 | $14.83 | $24.01 | +315% | Bullish | |
| $19.77 | $32.50 | $57.14 | +810% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.31 | $3.57 | $4.30 | +0.00% |
| September 2026 | $2.98 | $3.51 | $4.24 | -1.72% |
| October 2026 | $2.98 | $3.53 | $4.31 | +0.71% |
| November 2026 | $3.08 | $3.67 | $4.51 | +3.82% |
| December 2026 | $3.10 | $3.70 | $4.59 | +0.95% |
Click any year to see its month-by-month SABS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, SABS is projected to trade between $3.31 and $4.59, averaging $3.57 — a potential gain of 0% from today's $3.57. Price action looks broadly range-bound.
SAB Biotherapeutics, Inc.'s 2027 outlook centres on $4.53, within a $3.66 to $5.91 range. That is up +27% on the projected 2026 average. That marks a +27% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, SABS could reach as high as $7.82, with a base case around $5.80 and support toward $4.57 — roughly +62% from $3.57. Momentum favours further upside here.
Expect SABS to range from $4.69 to $8.41 through 2029. The $6.08 average target implies a +70% move from current prices. That is up +5% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The SABS price prediction for 2030 points to an average of $6.58 (low $4.99, high $9.30) — a potential gain of +84% on today's $3.57. Momentum favours further upside here.
In 2031, SABS is projected to trade between $5.45 and $10.52, averaging $7.30 — a potential gain of +105% from today's $3.57. That is up +11% on the projected 2030 average. Buyers look set to stay in control over this stretch.
SAB Biotherapeutics, Inc.'s 2032 outlook centres on $7.50, within a $5.52 to $11.00 range. That is up +3% on the projected 2031 average. That marks a +110% change versus current levels. Momentum favours further upside here.
By 2033, SABS could reach as high as $12.24, with a base case around $8.22 and support toward $5.96 — roughly +130% from $3.57. Buyers look set to stay in control over this stretch.
Expect SABS to range from $6.86 to $14.47 through 2034. The $9.57 average target implies a +168% move from current prices. That is up +17% on the projected 2033 average. Momentum favours further upside here.
The SABS price prediction for 2035 points to an average of $11.30 (low $8.00, high $17.31) — a potential gain of +217% on today's $3.57. Buyers look set to stay in control over this stretch.
In 2040, SABS is projected to trade between $9.92 and $24.01, averaging $14.83 — a potential gain of +315% from today's $3.57. That is up +31% on the projected 2035 average. Momentum favours further upside here.
SAB Biotherapeutics, Inc.'s 2050 outlook centres on $32.50, within a $19.77 to $57.14 range. That is up +119% on the projected 2040 average. That marks a +810% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in SABS today (≈ 280.112045 SABS) could be worth
$9,103.58
+$8,103.58 (+810%) by 2050 · US Dollar
Based on the average projected SABS price of $32.5 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SABSwould be worth at today's price.
$1,000 invested in SABS on Jul 31, 2025 (≈ 531.914895 SABS) would be worth
$1,898.94
+$898.94 (+89.9%) today · 1.90× · US Dollar
Based on a SABS entry price of $1.88 vs. today's $3.57.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.51 | $1,017.09 | +1.7% |
| 1 month ago | $3.88 | $920.1 | -8.0% |
| 3 months ago | $3.47 | $1,028.82 | +2.9% |
| 6 months ago | $4.38 | $815.07 | -18.5% |
| 1 year ago | $1.88 | $1,898.94 | +89.9% |
| All time (5.0y) ago | $98.9 | $36.1 | -96.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SABS forecast.
Our base-case forecast reaches $7.10 around 2031.
Implied market cap at $7.10: $542.9M
The multi-year forecast begins in 2026 with an average price of $3.62 and a neutral sentiment, with an implied 0% ROI. From 2027 onward, the outlook becomes bullish, with the average price rising to $4.84 in 2027 (ROI 33.6) and to $6.30 in 2028 (ROI 74), then continuing higher: 2029 $6.35 (ROI 75.5) and 2030 $7.07 (ROI 95.2). The trajectory extends to 2031 $7.87 (ROI 117.4) and 2032 $7.65 (ROI 111.2), then to 2033 $8.73 (ROI 141.2), 2034 $10.48 (ROI 189.4), and 2035 $12.22 (ROI 237.6).
Further out, 2040 shows $15.78 (ROI 335.9) and 2050 $35.62 (ROI 883.9), with bullish sentiment prevailing across the forecast. These are projections and not guarantees.
Tap a question to reveal the answer.
The 2030 average price is forecast at $7.07 with a maximum around $10.49 and a minimum around $5.15; the projected ROI is 95.2%.
The forecast shifts from Neutral in 2026 to Bullsih from 2027 onward, with rising averages and ROI (e.g., 2027 avg $4.84, ROI 33.6; 2030 avg $7.07, ROI 95.2; 2050 avg $35.62, ROI 883.9). These are estimates and not guarantees.
Yes. The forecast for 2030 lists a maximum price of $10.49.
The current price is $3.62 and the market capitalization is $276.8M.
The 30-day range was $2.97 to $4.41, with support at $3.31 and resistance at $4.00.
SAB Biotherapeutics, Inc. Community Discussion
0Share your SAB Biotherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.